Key result
Candesartan cilexetil reduced systolic/diastolic blood pressure by 8.6/4.8 to 11.2/8.0 mm Hg compared to 3.7/1.8 mm Hg with placebo (P<.01) in hypertensive children aged 6 to 17 years.
Why the study?
Does candesartan cilexetil reduce blood pressure in hypertensive children aged 6 to 17 years?
Population
240 hypertensive children aged 6 to 17 years (71% aged 12 years or older, 71% male, 47% black).
Comparison
Candesartan cilexetil for 4 weeks in the… vs Placebo for 4 weeks.
Design
RCT, randomized, double blind, placebo-controlled
Follow-up
4 weeks (RCT phase), 1 year (open-label phase)
Authors
Loading...
Supports candesartan use in pediatric hypertension; extends adult RCT evidence to ages 6-17.
RCT (n=240)
Double-blind
randomized
Does candesartan cilexetil reduce blood pressure in hypertensive children aged 6 to 17 years?
Effect estimate: placebo-corrected reduction of 4.9/3.0-7.5/6.2 mm Hg
p-value: p=<.01
Candesartan cilexetil is an effective and well-tolerated antihypertensive agent for children aged 6 to 17 years, with a pharmacokinetic profile similar to adults.
Trachtman et al. (2008) conducted an RCT in Hypertension (n=240). Candesartan cilexetil vs. Placebo was evaluated on Decline in systolic (SBP) and diastolic (DBP) blood pressure (placebo-corrected reduction of 4.9/3.0-7.5/6.2 mm Hg, p=<.01). Candesartan cilexetil reduced systolic/diastolic blood pressure by 8.6/4.8 to 11.2/8.0 mm Hg compared to 3.7/1.8 mm Hg with placebo (P<.01) in hypertensive children aged 6 to 17 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: